Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › metastasis

Metastasis

Part of Metastases

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for metastasis

9 trials tracked for metastasis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 24 citations.

9Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 5 Phase 1 1 Other / NA 2
  1. Phase 3 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine Completed · 24 cited
  2. Phase 2 A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer Completed
  3. Phase 2 Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer Completed
  4. Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Completed
  5. Phase 2 Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma Completed
  6. Phase 2 Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment Completed
Show 3 more trials
  1. Phase 1 Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors Completed
  2. N/A Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy Completed
  3. N/A Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Metastasis: what the trials found

Clinical investigations into metastatic disease have evaluated the efficacy of Dasatinib. Data indicate varying rates of objective response and disease control across different study cohorts, with reported disease control rates ranging from 6.67% to 16.13% 7.

In studies evaluating Dasatinib, the percentage of participants achieving a complete or partial response was recorded at 8.7% in one cohort compared to 0.0% in another 6. Additionally, specific cohorts showed progression-free survival (PFS) rates at various intervals (weeks 9, 17, and 25) ranging from 7% to 50% 7.

The use of NKTR-102 has been evaluated in a Phase 3 trial for this condition 2.

Recent results — preliminary, needs further review

  • A combination of SBRT and ADT demonstrated a median progression-free survival (PFS) of 6.0 months (p=0.001) in a study of 86 patients 1.

For the clinician treating this condition

  • Dasatinib shows inconsistent objective response rates but has been documented to provide disease control in some patient populations 7.
  • The combination of SBRT and ADT is associated with a statistically significant median PFS of 6.0 months 1.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Organ-specific metastatic niches at vascular-immune interfaces shape the fate of disseminated tumor cells
Allergy & Immunology Sys. Review
Organ-specific metastatic niches at vascular-immune interfaces shape the fate of disseminated tumor cells Specific Organ Environments Shape How Cancer Spreads to New Sites
This mini review explores how distinct organ microenvironments, including lung, liver, bone, and brain, influence metastatic progression. Th…
Cancer cells adapt to different parts of the body by interacting with local immune cells and blood vessels in specific areas like the lungs …
Frontiers Aug 26, 2026
Symmetry-informed inverse learning model evaluated for metastasis and Alzheimer disease detection on healthy brain MRI slices
Radiology & Imaging Cohort
Symmetry-informed inverse learning model evaluated for metastasis and Alzheimer disease detection on healthy brain MRI slices Normal Scans Reveal Hidden Brain Problems
This cohort study evaluated a symmetry-informed inverse learning foundation model using healthy brain MRI slices and external lesion dataset…
New brain scan analysis spots hidden problems by studying only healthy images, catching subtle issues that standard sick-brain training miss…
medRxiv Apr 16, 2026